GeNeuro: financial information and business update for the third quarter 2020

Geneva, Switzerland, October 19, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2020 third quarter cash position and issued a business update.